Jessica Peura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jessica Peura has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Jason R. Pitarresi
Division of Hematology–Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, USA
16 shared publications - Katherine C. Murphy
University of Massachusetts Chan Medical School 1 Department of Molecular, Cell, and Cancer Biology Worcester, Massachusetts
14 shared publications - Kelly D. DeMarco
University of Massachusetts Chan Medical School 1 Department of Molecular, Cell, and Cancer Biology Worcester, Massachusetts
14 shared publications - Lihua Julie Zhu
Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA
14 shared publications - Marcus Ruscetti
University of Massachusetts Chan Medical School 1 Department of Molecular, Cell, and Cancer Biology Worcester, Massachusetts
14 shared publications - Junhui Li
Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA
13 shared publications
Latest Publications
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S6 shows Representative flow gating strategy for immune populations in Myc-p53KO transplant prostate tumors.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S6 shows Representative flow gating strategy for immune populations in Myc-p53KO transplant prostate tumors.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S5 shows Elevated VEGFR2 expression in MYCHi human prostate cancers results in CD8+ T cell and DC suppression.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S5 shows Elevated VEGFR2 expression in MYCHi human prostate cancers results in CD8+ T cell and DC suppression.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Supplementary Table S2 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Supplementary Table S2 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S3 shows p53 inactivation in MYC-driven prostate tumors leads to reduced MHC-I expression and CD8+ T cell infiltration.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S3 shows p53 inactivation in MYC-driven prostate tumors leads to reduced MHC-I expression and CD8+ T cell infiltration.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S8 shows VEGFR2 targeting overcomes resistance to immune checkpoint blockade in MYC and p53 altered CRPC.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S8 shows VEGFR2 targeting overcomes resistance to immune checkpoint blockade in MYC and p53 altered CRPC.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S4 shows MYC and p53 altered prostate tumor cells produce VEGF that directly inhibits the activity of VEGFR2+ CD8+ T cells.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S4 shows MYC and p53 altered prostate tumor cells produce VEGF that directly inhibits the activity of VEGFR2+ CD8+ T cells.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S7 shows VEGFR2 blockade remodels the immune suppressive prostate TME on multiple levels and independently of its effects on vascular remodeling to activate effector T cells specifically in MP tumors.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S7 shows VEGFR2 blockade remodels the immune suppressive prostate TME on multiple levels and independently of its effects on vascular remodeling to activate effector T cells specifically in MP tumors.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S1 shows Genetic subtypes of murine AVPC display different immune milieus.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S1 shows Genetic subtypes of murine AVPC display different immune milieus.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S2 shows MYC and PTEN co-alterations do not cooperate to further drive immune suppression or lethality in human prostate cancer.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Figure S2 shows MYC and PTEN co-alterations do not cooperate to further drive immune suppression or lethality in human prostate cancer.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Data from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Patients with castration-resistant prostate cancer (CRPC) are generally unresponsive to tumor-targeted treatments and immunotherapies. Genetic alterations acquired during the evolution of CRPC may affect antitumor immunity and immunotherapy responses, which could inform personalized therapeutic strategies. Using our innovative electroporation-based mouse models, we generated distinct genetic subtypes of CRPC found in patients and uncovered unique immune microenvironments. Specifically, mouse and human prostate tumors with MYC amplification and p53 disruption had weak cytotoxic lymphocyte infiltration and an overall dismal prognosis. MYC and p53 cooperated to induce tumor-intrinsic secretion of VEGF, which signaled through VEGFR2 expressed on CD8+ T cells to directly inhibit T-cell migration and effector functions. Targeting VEGF–VEGFR2 signaling in vivo remodeled the immunosuppressive prostate tumor microenvironment, leading to CD8+ T-cell–mediated primary tumor and metastasis growth suppression and significantly increased overall survival in MYC- and p53-altered CRPC. VEGFR2 blockade also led to the induction of PD-L1 in tumors and produced antitumor efficacy in combination with PD-L1 immune checkpoint blockade in multiple preclinical CRPC mouse models. Thus, these results identify a genetic mechanism of immunosuppression through VEGF signaling in prostate cancer that can be targeted to reactivate immune and immunotherapy responses in an aggressive subtype of CRPC.Significance:VEGFR2 blockade inhibits VEGF-mediated T-cell suppression and potentiates the effects of PD-L1 immune checkpoint blockade to treat castration-resistant prostate cancer driven by MYC and p53 alterations.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Patients with castration-resistant prostate cancer (CRPC) are generally unresponsive to tumor-targeted treatments and immunotherapies. Genetic alterations acquired during the evolution of CRPC may affect antitumor immunity and immunotherapy responses, which could inform personalized therapeutic strategies. Using our innovative electroporation-based mouse models, we generated distinct genetic subtypes of CRPC found in patients and uncovered unique immune microenvironments. Specifically, mouse and human prostate tumors with MYC amplification and p53 disruption had weak cytotoxic lymphocyte infiltration and an overall dismal prognosis. MYC and p53 cooperated to induce tumor-intrinsic secretion of VEGF, which signaled through VEGFR2 expressed on CD8+ T cells to directly inhibit T-cell migration and effector functions. Targeting VEGF–VEGFR2 signaling in vivo remodeled the immunosuppressive prostate tumor microenvironment, leading to CD8+ T-cell–mediated primary tumor and metastasis growth suppression and significantly increased overall survival in MYC- and p53-altered CRPC. VEGFR2 blockade also led to the induction of PD-L1 in tumors and produced antitumor efficacy in combination with PD-L1 immune checkpoint blockade in multiple preclinical CRPC mouse models. Thus, these results identify a genetic mechanism of immunosuppression through VEGF signaling in prostate cancer that can be targeted to reactivate immune and immunotherapy responses in an aggressive subtype of CRPC.Significance:VEGFR2 blockade inhibits VEGF-mediated T-cell suppression and potentiates the effects of PD-L1 immune checkpoint blockade to treat castration-resistant prostate cancer driven by MYC and p53 alterations.